SI2922848T1 - Derivati oksazolidin-2-on-pirimidina - Google Patents

Derivati oksazolidin-2-on-pirimidina

Info

Publication number
SI2922848T1
SI2922848T1 SI201330782T SI201330782T SI2922848T1 SI 2922848 T1 SI2922848 T1 SI 2922848T1 SI 201330782 T SI201330782 T SI 201330782T SI 201330782 T SI201330782 T SI 201330782T SI 2922848 T1 SI2922848 T1 SI 2922848T1
Authority
SI
Slovenia
Prior art keywords
oxazolidin
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
SI201330782T
Other languages
English (en)
Slovenian (sl)
Inventor
Robin Alec Fairhurst
Pascal Furet
Frank Stephan Dr. KALTHOFF
Andreas Lerchner
Heinrich Rueeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2922848T1 publication Critical patent/SI2922848T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201330782T 2012-11-12 2013-11-11 Derivati oksazolidin-2-on-pirimidina SI2922848T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725113P 2012-11-12 2012-11-12
PCT/IB2013/060052 WO2014072956A1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
EP13795867.4A EP2922848B1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
SI2922848T1 true SI2922848T1 (sl) 2017-10-30

Family

ID=49667527

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330782T SI2922848T1 (sl) 2012-11-12 2013-11-11 Derivati oksazolidin-2-on-pirimidina

Country Status (42)

Country Link
US (3) US9296733B2 (enExample)
EP (2) EP2922848B1 (enExample)
JP (1) JP6262245B2 (enExample)
KR (1) KR102153763B1 (enExample)
CN (1) CN104718204B (enExample)
AP (1) AP2015008347A0 (enExample)
AR (1) AR093408A1 (enExample)
AU (1) AU2013343022B2 (enExample)
BR (1) BR112015010136A2 (enExample)
CA (1) CA2890942C (enExample)
CL (1) CL2015001202A1 (enExample)
CO (1) CO7380758A2 (enExample)
CR (1) CR20150248A (enExample)
CU (1) CU24365B1 (enExample)
CY (1) CY1119391T1 (enExample)
DK (1) DK2922848T5 (enExample)
EA (2) EA027987B1 (enExample)
EC (1) ECSP15025093A (enExample)
ES (1) ES2641820T3 (enExample)
HR (1) HRP20171425T1 (enExample)
HU (1) HUE034492T2 (enExample)
IL (1) IL238239A (enExample)
IN (1) IN2015DN02912A (enExample)
JO (1) JO3334B1 (enExample)
LT (1) LT2922848T (enExample)
MA (1) MA38076A1 (enExample)
MX (1) MX363436B (enExample)
MY (1) MY174239A (enExample)
NZ (1) NZ706591A (enExample)
PE (1) PE20151006A1 (enExample)
PH (1) PH12015501053B1 (enExample)
PL (1) PL2922848T3 (enExample)
PT (1) PT2922848T (enExample)
RS (1) RS56336B1 (enExample)
SG (1) SG11201503447QA (enExample)
SI (1) SI2922848T1 (enExample)
TN (1) TN2015000120A1 (enExample)
TW (1) TWI608005B (enExample)
UA (1) UA114001C2 (enExample)
UY (1) UY35128A (enExample)
WO (1) WO2014072956A1 (enExample)
ZA (1) ZA201502175B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500682A1 (en) 2011-09-27 2014-05-12 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
HK1258696A1 (zh) 2015-09-24 2019-11-15 Drexel University 治療或預防皮膚障礙的新型組合物和方法
EP3458035A1 (en) * 2016-05-18 2019-03-27 PIQUR Therapeutics AG Treatment of skin lesions
JP7118509B2 (ja) 2016-05-18 2022-08-16 トルク アーゲー 皮膚病変の治療
TW201929861A (zh) 2017-11-06 2019-08-01 瑞士商諾華公司 包含㗁唑啶-2-酮-嘧啶衍生物之調配物
CN111315384A (zh) 2017-11-23 2020-06-19 皮奎尔治疗公司 皮肤病的治疗
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921148B1 (enExample) 1970-12-28 1974-05-30
JPS4921149B1 (enExample) 1970-12-28 1974-05-30
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (en) 1988-02-25 1989-08-30 Merck & Co. Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
ATE139117T1 (de) 1990-07-03 1996-06-15 Mitsui Petrochemical Ind Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz
US5786355A (en) 1995-04-13 1998-07-28 Taiho Pharmaceutical Co., Ltd. 4,6-diarylpyrimidine derivatives and salts thereof
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
CA2297326C (en) 1997-07-24 2007-03-20 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active component
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
SI0930302T1 (en) 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
AU768201B2 (en) 1999-01-22 2003-12-04 Amgen, Inc. Kinase inhibitors
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc Links to SRC kinase inhibition
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
EP1196411B1 (en) 1999-07-15 2003-09-17 Pharmacopeia, Inc. Bradykinin b1 receptor antagonists
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
CA2401748A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
MXPA03002297A (es) 2000-09-15 2003-06-06 Vertex Pharma Compuestos de triazol utiles como inhibidores de proteina cinasa.
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
ES2375491T3 (es) 2000-12-21 2012-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol útiles como agentes inhibidores de las prote�?na-quinasas.
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
WO2002096876A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1485380B1 (en) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
DE60327999D1 (de) 2002-03-15 2009-07-30 Vertex Pharma Azolylaminoazine als inhibitoren von proteinkinasen
WO2003077921A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en) 2002-03-15 2003-09-29 Binch, Hayley Compositions useful as inhibitors of protein kinases
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
JP2006515274A (ja) 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
CA2507100C (en) 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN101468965A (zh) 2003-03-24 2009-07-01 默克公司 联芳基取代的6元杂环钠通道阻滞剂
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
JP4895806B2 (ja) 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
EP1651619A1 (en) 2003-07-15 2006-05-03 Neurogen Corporation Substituted pyrimidin-4-ylamin analogues as vanilloid receptor ligands
WO2005007648A2 (en) 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
DE602005024382D1 (de) 2004-04-13 2010-12-09 Astellas Pharma Inc Polycyclische pyrimidine als kaliumionenkanal-modulatoren
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
CA2587642C (en) * 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
CN101080228A (zh) 2004-12-13 2007-11-28 神经能质公司 哌嗪基－吡啶类似物
EP1824839A2 (en) 2004-12-13 2007-08-29 Neurogen Corporation Substituted biaryl analogues
CN101184734B (zh) 2004-12-28 2013-05-29 金克斯医药品有限公司 治疗细胞增殖紊乱的化合物和方法
WO2006078992A2 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
JP2008531537A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 化合物
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
CA2635997A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2012794B1 (en) * 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions and intraluminal devices for inhibiting vascular stenosis
TW200833342A (en) 2006-12-28 2008-08-16 Basf Ag 2-substituted pyrimidines I in therapy
MX2009008341A (es) 2007-02-06 2009-08-12 Novartis Ag Inhibidores de cinasa de pi3 y metodos para su uso.
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
CA2692945A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Compounds - 945
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
AU2009221164B2 (en) 2008-03-05 2012-07-26 Novartis Ag Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
US20110020338A1 (en) 2008-03-26 2011-01-27 Carlos Garcia-Echeverria 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes
US20110053907A1 (en) 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
EP2280948A1 (en) 2008-04-09 2011-02-09 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CN102202668A (zh) 2008-10-31 2011-09-28 诺瓦提斯公司 磷脂酰肌醇-3-激酶(PI3K)抑制剂和mTOR抑制剂的组合产品
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
MX2011008243A (es) 2009-02-06 2011-08-17 Nippon Shinyaku Co Ltd Derivados y medicina de aminopirazina.
JP5747440B2 (ja) 2009-02-06 2015-07-15 住友化学株式会社 ヒドラジド化合物及びその有害生物防除用途
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
ES2417355T3 (es) 2009-05-19 2013-08-07 Dow Agrosciences Llc Compuestos y métodos para el control de hongos
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
PH12012500491A1 (en) 2009-09-09 2018-03-21 Celgene Avilomics Res Inc P13 kinase inhibitors and uses thereof
EP2509600B1 (en) 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
CA2805669C (en) 2010-07-16 2018-08-21 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
PE20140002A1 (es) 2010-10-01 2014-01-21 Novartis Ag Proceso de elaboracion para derivados de pirimidina
SI2629776T1 (sl) 2010-10-18 2017-12-29 Cerenis Therapeutics Holding Sa Spojine, sestavki in postopki, uporabni za mobilizacijo holesterola
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2012109423A1 (en) 2011-02-11 2012-08-16 Dana-Farber Cancer Institute, Inc. Method of inhibiting hamartoma tumor cells
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CA2846272A1 (en) 2011-09-01 2013-03-07 Novartis Ag Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone
PH12014500682A1 (en) 2011-09-27 2014-05-12 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2013052395A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
KR20150009540A (ko) * 2012-05-16 2015-01-26 노파르티스 아게 Pi-3 키나제 억제제에 대한 투여 요법
CA2872541A1 (en) 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
IN2015DN00528A (enExample) 2012-08-16 2015-06-26 Novartis Ag
ES2605638T3 (es) 2012-10-23 2017-03-15 Novartis Ag Proceso Mejorado para fabricar 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX2015012822A (es) 2013-03-14 2016-05-31 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
CN103483345B (zh) 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
CN103694218B (zh) 2013-12-05 2016-04-27 中山大学 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用

Also Published As

Publication number Publication date
EA029714B1 (ru) 2018-05-31
US20160168145A1 (en) 2016-06-16
AU2013343022A1 (en) 2015-04-23
TWI608005B (zh) 2017-12-11
IN2015DN02912A (enExample) 2015-09-11
HUE034492T2 (en) 2018-02-28
EP2922848A1 (en) 2015-09-30
CR20150248A (es) 2015-07-01
ECSP15025093A (es) 2019-03-29
US20140135330A1 (en) 2014-05-15
WO2014072956A1 (en) 2014-05-15
CA2890942A1 (en) 2014-05-15
JO3334B1 (ar) 2019-03-13
EP3199158A1 (en) 2017-08-02
EP3199158B1 (en) 2019-04-17
CL2015001202A1 (es) 2015-07-03
MX2015005914A (es) 2015-09-08
JP6262245B2 (ja) 2018-01-17
KR20150082295A (ko) 2015-07-15
DK2922848T3 (da) 2017-10-09
CN104718204A (zh) 2015-06-17
CO7380758A2 (es) 2015-09-10
ZA201502175B (en) 2018-05-30
EP2922848B1 (en) 2017-06-28
SG11201503447QA (en) 2015-05-28
CU20150050A7 (es) 2015-11-27
AR093408A1 (es) 2015-06-03
MY174239A (en) 2020-04-01
PL2922848T3 (pl) 2017-12-29
AU2013343022B2 (en) 2015-08-20
US10202371B2 (en) 2019-02-12
CN104718204B (zh) 2017-11-28
RS56336B1 (sr) 2017-12-29
US20190382399A1 (en) 2019-12-19
EA027987B1 (ru) 2017-09-29
IL238239A (en) 2017-05-29
KR102153763B1 (ko) 2020-09-09
UA114001C2 (xx) 2017-04-10
PE20151006A1 (es) 2015-07-04
HRP20171425T1 (hr) 2017-11-17
LT2922848T (lt) 2017-09-25
EA201590929A1 (ru) 2015-08-31
PH12015501053A1 (en) 2015-07-27
JP2015536974A (ja) 2015-12-24
CY1119391T1 (el) 2018-02-14
PT2922848T (pt) 2017-10-05
ES2641820T3 (es) 2017-11-14
DK2922848T5 (en) 2017-10-30
MA38076A1 (fr) 2018-02-28
AP2015008347A0 (en) 2015-04-30
PH12015501053B1 (en) 2015-07-27
HK1209108A1 (en) 2016-03-24
UY35128A (es) 2014-06-30
BR112015010136A2 (pt) 2017-07-11
EA201790289A1 (ru) 2017-06-30
TN2015000120A1 (en) 2016-06-29
CA2890942C (en) 2021-01-12
MX363436B (es) 2019-03-22
TW201427974A (zh) 2014-07-16
CU24365B1 (es) 2018-10-04
US9296733B2 (en) 2016-03-29
NZ706591A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
ZA201409422B (en) Benzimidazole-proline derivatives
DK3327112T3 (en) Agse-deficient stamme
ZA201408876B (en) Pyrrolotriazinone derivatives
EP2935220A4 (en) PERI-carbinol
PT2838883T (pt) Novos derivados de fenil-tetra-hidroisoquinolina
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
IL236295A (en) The history of indanesulfamide
EP2920142A4 (en) MÉTHANOFULLERRÈNES
ZA201405108B (en) Substituted phenylazole derivative
PT2873660T (pt) Derivado de indolecarboxamida
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
GB201202648D0 (en) Xstyler
GB201202382D0 (en) Flexfix
GB201202303D0 (en) Myhealthbadge
GB201202208D0 (en) Easomark
GB201201023D0 (en) Sharkbitze
GB201201085D0 (en) Hit-a-pair
GB201200939D0 (en) Drinc-pinc
GB201202335D0 (en) Cabb
GB201200644D0 (en) Visualiser
GB201200608D0 (en) Torsocooler
GB201200605D0 (en) Buttermesh
GB201200467D0 (en) Coda251
GB201200226D0 (en) Kinibra
GB201200011D0 (en) Eggboiler